A Study of ARRY-371797 in Patients With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study, involving a 29-day treatment period, designed to evaluate the
pharmacokinetics and the effectiveness of investigational study drug ARRY-371797 in treating
rheumatoid arthritis in patients receiving stable doses of methotrexate, and to further
evaluate the drug's safety. Approximately 30 patients from the US will be enrolled in this
study.
Phase:
Phase 1
Details
Lead Sponsor:
Array BioPharma Array Biopharma, now a wholly owned subsidiary of Pfizer